MedPath

Miltenyi Biotec B.V. & Co. KG

🇩🇪Germany
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 3:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 3
1 (33.3%)

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Not Applicable
Terminated
Conditions
Acute Myelogenous Leukemia
First Posted Date
2017-05-15
Last Posted Date
2020-07-09
Lead Sponsor
Miltenyi Biotec B.V. & Co. KG
Target Recruit Count
1
Registration Number
NCT03152526
Locations
🇺🇸

Universtiy of Chicago, Chicago, Illinois, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension

Not Applicable
Completed
Conditions
Idiopathic Pulmonary Arterial Hypertension
First Posted Date
2012-06-07
Last Posted Date
2020-07-10
Lead Sponsor
Miltenyi Biotec B.V. & Co. KG
Target Recruit Count
12
Registration Number
NCT01613287
Locations
🇩🇪

Thoraxklinik am Universitätsklinikum Heidelberg in cooperation with Nierenzentrum Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany

🇩🇪

Universitätsmedizin Greifswald, Zentrum für Innere Medizin, Klinik und Poliklinik für Innere Medizin B, Greifswald, Mecklenburg-Western Pomerania, Germany

🇩🇪

Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin und Zentrum für Molekulare Medizin, Cologne, North-Rhine Westphalia, Germany

and more 1 locations

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Phase 3
Terminated
Conditions
Myocardial Ischemia
Coronary Artery Disease
Interventions
Drug: CD133+ autologous bone marrow stem cell
Drug: Placebo
First Posted Date
2009-07-31
Last Posted Date
2020-07-15
Lead Sponsor
Miltenyi Biotec B.V. & Co. KG
Target Recruit Count
81
Registration Number
NCT00950274
Locations
🇩🇪

Herz- und Diabeteszentrum Nordrhein Westfalen, Bad Oeynhausen, Germany

🇩🇪

Deutsches Herzzentrum Berlin, Berlin, Germany

🇩🇪

Universitäres Herzzentrum Hamburg, Hamburg, Germany

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.